# A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen

> **NCT01070290** · PHASE2 · WITHDRAWN · sponsor: **ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)**

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** ARQ 197
- **DRUG:** Oxaliplatin, capecitabine or irinotecan

## Key facts

- **NCT ID:** NCT01070290
- **Lead sponsor:** ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01070290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01070290, "A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01070290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*